CRIS Curis Inc.

2.14
0  0%
Previous Close 2.14
Open 2.17
Price To Book -3.51
Market Cap 71,054,144
Shares 33,202,871
Volume 25,975
Short Ratio
Av. Daily Volume 118,558
Stock charts supplied by TradingView

NewsSee all news

  1. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1,

  2. Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  3. Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

    LEXINGTON, Mass., Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data released August 6, 2019. Further update due later in 2019.
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 mesothelioma data due 2H 2019.
CA170
Solid Tumors and Lymphomas
Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 1b initial data in DH/DE DLBCL 2H 2019.
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1,

  2. Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer,

  3. Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

    LEXINGTON, Mass., Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill